VYGR - Earnings call transcript Q4 2018 | Voyager Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Voyager Therapeutics' Fourth Quarter and Year-End 2018 Financial Results and Corporate Highlights Conference Call. At this time, all participants are in a listen-only mode.

Following the formal remarks, we will open up the call for your questions. Please be advised that this call is being recorded at the Company's request. At this time, I'd like to turn the call over to Matt Osborne, Voyager's Vice President of Corporate Affairs, Communications and Investor Relations. proceed. Please

Matt Osborne

fourth afternoon, a the the our press corporate for Good afternoon, call. results corporate welcome end is highlights issued year available guidance we release, the The goals and and you. and for conference to This and of financial Thank XXXX and XXXX. provides release quarter which voyagertherapeutics.com. outlines at

XXXX, call that Voyager represent update to differ just law. refer begin, over as statements such to forward-looking as I'll we concerning today, to materially Voyager's expressed call the February to any or for statements. well required pass a of disclaims could reminder XXth, information the Company's release risk SEC obligation these the reflect in or today's Before view future as filings factors With with by as to cause this circumstances, that, from Andre. implied included statements press Please events those by the that results except actual

Andre Turenne

Thank good afternoon start to of you and Welcome you, the of Matt, call our XXXX. corporate I'll for summarizing start by and developments our review since highlights. year-end key everyone.

XXXX capsids. discuss us the our collaborations. you antibody the of in and entered success each significantly deals steps collaborations team, manufacturing year we've our for into detail strengthened position two entered We've in in and developments major also to on start programs. platform then a We've these of vision into support our product, integrated how and and invest our XXXX capabilities. since our start engine, how important outline of our We've I'll guidance. to results they we've strategic discovery financial XXXX Company. beyond. a give new lead biopharmaceutical strategic this and our will becoming of I'll fully vectorized Next, present these will more expanded pipeline took advancing and novel who and continued leading tremendous I has goals, over before it XXXX. Allison, turning Voyager We had management

VY-AADC for we randomized first, conduct a guidance of with into trial II trial. FDA feedback. earlier the two We We So disease, December, trials investigator their meetings. meeting productive In the the the RESTORE-X on Type-B Parkinson's to gaining initiated held enrolling we clarity Phase for placebo-controlled we've two and design planned their and the recently well-attended adequate well-controlled started RESTORE-X RESTORE-X and incorporate held trial. RESTORE-X

as believe and to brain's with to patients better it dopamine follow-up positive years open-label X. years all announced Cohort the we and XXXX, the response response restore in long-term their from function, trial Phase long-term November, with we follow-up X, escalating VY-AADC. encouraged make We're demonstrate continues three During similar motor can cohorts the data dose more with ability In data patients Cohort the from to earlier of VY-AADC X, from stages disease. therapy, XX Cohort to months Xb levodopa during we the in shared allowing that two three data of to in results their provide post-treatment control

pipeline best-in-class progressed clinic. programs advancing also have on well programs focused We're during potentially preclinical the probability Our high very year. into success a of that the

areas vectors our the each to We are in to spinal capsid, these and provided regions the delivery cell and on preclinical ESGCT delivery our preclinical disease one-time applied transgene of ways of as meeting, those well as to we disease both optimize fall, the the the unique Our efforts prominently approaches within that types at cord ALS updates of contribute leveraged and In Huntington's target programs. relevant brain ongoing manifestations. the most programs. to

XX% the VY-SODXXX our and respiration. cord able of to in thalamus reduction an animals gene were achieve file in significant layers expression VY-HTTXX of under for large of delivery throughout over SODX a Preclinical the deeper toxicology motor maintaining of with Huntington's the in SODX this for neurons, for of resulted with which critical reduction are of in programs INDs administration cord we spinal SODX-ALS, And For into and of the program, animals, studies cervical including of HTT significant large brain. tissues are other putamen these later gene potential year. way reduction expression to both of spinal

discovery our efforts. advanced and also We capsids antibody novel vectorized programs

directly expanded the antibody. with on advancements AbbVie an made work alpha-synuclein approach leveraged the tau be latter, our antibody on vectorized On will vectorized in

scale continue to front, our manufacturing competencies as capabilities Diosynth our the add manufacturing into Bio our we flexibility pipeline and supply. I to entered and across ensure and while we in-house in contract arrangements add to best-in-class baculo/SfX internal expertise strategic process adequate development. and and then we and Fujifilm On clinical leverage with commercial recall Brammer to around core with our manufacturers partner We'll

as continue Counsel, AbbVie. Bob collaborations; Over General as with Chief the the And the key achievements of with conclude, Officer, in of executive and of Dorval to Chief partner in past working into Khwaja we've summary entered months, the XXXX, team since to Allison enabling and one to Hesslein and we've strengthened also to with and lastly, I'm appointments two Bob weeks coming with with three Omar significantly start strategic management role. her Neurocrine new and Financial Omar as Officer. Medical the begin excited our formally Allison

the programs. joint leader previously partnering forward two and with look benefit and As insights access Neurocrine Neurocrine's We to on discussed, us our in them with from selecting aligns Parkinson's FA disorders. movement discovery to our contributions. experience, new clearly collaboration true and We'll to a

target diseases. neurological alpha-synuclein. gene now toward becoming We to leading We've these a the we our tau relationship the to support promising and week transactions last on strategy therapy since antibodies new move on on fully year. just got with vectorized also vectorized antibody announced past on I comment in focused in last collaboration how want of Company integrated severe separate productive of expansion Friday, February AbbVie our announced a the collaborations two

partner allow the X. funds to payments Phase but product as for rights. future two case and we more targets in in the think a with to our quality that advanced with near-term discovery programs non-dilutive or pre-funds payments two the high programs benefit collaborations development and our pipeline pursue retain own fund were commercial prior the engine programs fully a In I can IND Neurocrine, AbbVie with The in from over both were partner with or and is alone of at discovery research one don't eligible the we novel advancing ways. partner start, after for three turn us the way, turning or program These to milestones way.

for retained eligible partners candidates the million years ADC rights. over programs preclinical In a to across resources, existing capable the $XXX from than up sharing is for partners and milestone with are more as significant and the but programs. co-development Neurocrine, support of provides We with with funding This ability multiple us payments our FA to with advanced the derive and highly and value program case in these in development way, and programs co-commercialization form of risk with programs. HD we the our another Sanofi, coming

both fully goals year year. leading toward for advance our to to as case to assets Finally, efforts, additional will the this SODX-ALS to for full a goal in be become adding to in on upside me own the and In therapy focused Company and severe our which promising and the is takes our internal diseases. programs we execute portfolio for way, fully disclosed, platform this continue through retained the be intend and Company value. our our programs retained XXXX, BD integrated third we advanced on we as to XXXX neurological an programs, important invest further program gene

from open VY-AADC XX-month label, in disease plan Phase function motor posterior with infusion data treated trajectory. we with safety the patients of X Next and quarter, the Parkinson's to provide trial

sites the trial. and activation Next, to we continue to plan patients enroll complete in RESTORE-X of trial

year, of longer label, toxicology the to later trials, our way term the are filings open IND year. preclinical plan data to we pharmacology X During both ALS-SODX and life this potential to programs of trial motor disease from and support safety toward X ongoing of and for function applications Phase under Huntington's programs clinical biomarker, studies advance plan Cohorts We X VY-AADC. quality from provide to

plan and new discovery evaluate identify program enabling of and identification toward candidates development pharmacology and In continue lead business we'll programs, advance addition, and preclinical IND and ataxia to to in finally, potential antibody our continue the Friedreich's capsid development. platform toxicology we invest opportunities studies. And to vectorized

look very to time and review exciting hopefully as I our Voyager. on Allison, to developments for these With the the it that, will goals progress So I'll updating financials. year. forward throughout turn the against our you it's other captured, over who a summary

Allison Dorval

year costs including and and quarter XXXX. $X.X year guidance Sanofi XXXX. to December financials fourth related period $X.XX the The and primarily of minutes December of Andre. under for efforts per million the revenues trial quarter $X.X for December million increase of $XX.X loss reported the compared Q&A. XXXX or spend revenues can for for quarterly million to XXXX. same Phase and compared the December few the XXXX. the quarter we per the $X.X collaborations. the periods to Collaboration revenues for clinical the The the the to pipeline the programs. ended same million based fourth of same increase recognition programs ended quarter support of the fourth XXXX full Sanofi $X.XX fourth XXXX XXXX fourth agreements, for collaboration our expenses to in expenses VY-AADC, full for XXXX. vary in year and year of loss compared quarter I'll quarter the G&A $XX.X of consulting GAAP support million share were XXXX growing AbbVie the ended Genzyme's partially of personnel XX, in expenditures compared XX, $XX.X million costs period expenses next quarter fourth of or ended revenues for the development January XXXX of collaboration reflect of related or in GAAP period X, revenues XXXX reviewing and associated one-time methodology. to quarter development revenue advancement of These decrease into to million a and entered same adoption for personnel for research Parkinson's the our our professional a we rights to and the offset fourth the for XXXX. for year addition AbbVie share G&A GAAP increased per costs the million in to collaboration a compared from for $X.X the our facility $XX.X facility by was of loss per The payments reflect in fourth to for fourth million and services in for recognition net expenses $X.XX in with compared on $XX.X share the for recognition XX, X the the General amounts $XX.X to Thanks. our RESTORE-X or assessments to XXXX XXXX net move decreases in expenses million the allocated XXXX business. for modified net February to the collaboration fourth the of various collaboration the share which Genzyme XXXX. loss quarter accounting revenue standards XX, in to provided of Collaboration compared December due million of $XX.X was agreement of December same to for ended of R&D pipeline $XX.X compared that administrative R&D R&D primarily million million including XX, ended XXXX. before $X.XX million XX, the XXXX $XX.X quarter Voyager of of legal period and $XX.X program million expenses the of of revenues $XX.X ended for of under compared costs in full new XXXX to XXXX. net the for GAAP with to $X.X and Collaboration increased fees million in

million ended of guidance. of proceeds common in upfront million $XXX turning Abbvie Neurocrine with to additional million Neurocrine. We XXXX the $XX collaboration marketable expect our sale our from from planned toward receive debt securities and cash inclusive on stock of and Now cash, equivalents the $XXX.X payments we and to an

of to development recorded as operating and vectorized these will We be revenue. $XXX These expect discovery ongoing reimbursement capsids the any pipeline expenses $XXX as invest advance agreements, our range and the efforts. million costs to collaboration we exclude expenses be collaboration the in infrastructure to support in since operating of our under programs, antibody robust million amounts novel and our

programs securities, will our two with $XXX the Neurocrine like to million reminder, $XXX million have end Based Parkinson's up we opt-in operating four questions, all debt including operator? plan, on current development that, for to costs to believe rights. mid expect a needs we call the which collaboration for be which and our funding programs would we Ataxia, Friedreich's to XXXX. As on meet for cash, now of operating sufficient marketable we equivalents to With the and be open into cash XXXX

Operator

James. [Operator from comes Instructions] Leone Our question first with Raymond Dane

Dane Leone

color guys questions want couple and A Maybe I ask from what give me. expansion a the year. curious, relationship catalyze here, the date the to congrats the actually just to Hi. can just partnership? that taking the strong you've little kind the that you start of of deal, Thank for expansion the in delivered bit the I'm AbbVie strategic on was of of on relationship you to of helped great, of kind us

Andre Turenne

the Yes, Dane. for thanks question,

So it's we're very been almost into a exactly tau relationship the working a with relationship. close and AbbVie year on

and high models novel a looking distribution tau. to vectorize what been this in test a so number of level, different the select, capsids at we've in using So far models these. research able pharmacology to various parties are clone, both targeting starting to evaluating animal has AAV and it's be done antibodies evaluate been work in We've at to contributing

we them very time and interesting was work done to able AbbVie compelling. So, that quite to leverage us be short with it able working target of to add in a hand-in-hand be that with work be bit think for all of to able a amount to is to of a

lot from think positive belt, it bit of I a amount in applying a to of target. momentum but both and quite interest So perspective, of time short another under the

Dane Leone

approved that clinically of on reductions a of impactful, the where your feeling out daily there, focused hear basis? to integrating updated are community there could UPDRS now you're in X/X One, as technology where program, Few points you and with RESTORE and the at or terms commentary. think they're held. and going have really of the endpoints the of if then follow just MRI now from in the been the the correlated have kind of part whether guided the second of what's from investigators move just more up studies, from And of I administration are just the investigator your meeting to with interest investigators what's with toward endpoints Great. investigators recently you. reception? kind you -- that clinical of there that in the these is feedback number thoughts thankfully real pivotal it's be critical on they some curious seem that V-TAG on is the Thank with technology they've VY-AADC, levodopa that and feedback the the expressing your that you of a I'm but all been load

Andre Turenne

these start addressing ask thanks to with I'll for questions, Matt these. Yes,

Matt Osborne

Osborne Hi, Matt Dane. [Ph]. Sure.

questions So a couple in of there. different

expanding RESTORE-X we So down have break for clinical involved group years. I'd a beyond of new been the into investigators, the to it with the trial, the with number for core program sites that are

life. the quality the of the totality Parkinson's, seeing out that to discussions, very see seeing And of most as in -- patient is really of evident activity of terms reduction then of as levodopa, brain you're medication the around that so this and enzyme of measures alignment is across it improvement oral the previously one how the recalling what as physician for part where and elegant had is both remarkable time the that I'd of of all the it's not compelling over the into them replacing to then when it's is being things diary program enzyme result a initial measures they able than was the in well say stands that we translate that across very actually getting see data in and the as strong

-- of a Phase through the be gold we neurosurgery which but that and in MRI a in way consistent early something the really on, Interventions, a expectation what functional is studies. and the direction is potentially the That's this you the potential of that the at pivotal there's increasing question, when reduction all across focused moving community on the improvement then time that we've of in the ClearPoint optimized oral and Phase-X. the into good adopted Phase-X a program. We're line the improving being regulatory. of used the that, the part to your in guide well the the the really primary part lot endpoint diary the dose really then really a looking course and kind placebo-controlled plant based expecting response. much between [Ph], manner, oral seeing with That's seeing a gets medications, titration very invested these standard excited and that months. we shift them and is of as trial the dose lower the delivery Phase To second to the X on blinded aspect focused and what of going heading point study regulatory at is That's of System, ability the the in conversations about the then impact forward one the focused delivery, it's was the reported on on So the optimizing dose-dependent X around the time in on land secondary study and at them we've was we up experience, and Then, XX focusing into the the cohorts again the in really a but seen really to which measures that run that are medication.

also developed our that we internally, you ClearPoint so that now not System, that XXX(NYSE:K) we are We fit-for-purpose have from a own device have sites to add has described device the provide flexibility as approval yet FDA. adopted introducing can the the

we activate move the be that that so as and that with parallel, and rolling out to as are have in that flexibility program. we expect forward We happening we sites would

use how point that really have decision do on we it's the a preference Our to not is between view site-specific of want a they two, it.

Dane Leone

Excellent. Thank you much. very

Operator

Our with Nomura. Christopher next Marai from question comes

Jackson Harvey

fitting Christopher curious on Harvey just I to collaboration AbbVie if how Hello, this on could speak bit vectorized the for was this just see is the Marai. antibodies, Jackson you a with you little into blood-brain you. the the of Thank even technologies AbbVie's program thinking I'm barrier competitive landscape for Denali's receptor emerge. dual the particular, as targeted transferrin more crossing antibodies. In and own

Andre Turenne

Thanks your for question, Jackson. Yes.

is [Ph] challenge for been it the years. something many, for So many sales that's a

with being to So of payload the attempted it's is novel encode or of antibody number there get and an be an the right, leverage the thing CNS. thing our delivery able capability a to sequence to across be antibody good approaches get the -- that to blood-brain barrier. broadly What better the is for fragment natural through a distributed to a our able we to capsids sales the penetrance here

eventually, something opened efforts get as we the to non-human that into the therapeutic seeing advance ability a we how for our get a efforts primates, to So of are get fare, Fortis we delivery significantly in the stability will early get clinic and CNS to is enhanced across across but we basis [Ph]. our see is into to tell payload the we models and eventually animal to and

vectorizing can to vehicle. can with you and same that that the an for able you our with incorporate, of can of this, success advantages then one other if the capsids that permutations being of antibody the with have payloads -- -- therapeutic one we you you that's achieve novel can have that Now, number the is the deliver in payloads

just as AbbVie going in antibody to but to start development thought on are to to -- well, place to we So explore two these compelling look expert was right work with we're the instep, the and targets that start. things in

Jackson Harvey

on congratulations Great, thank your you progress. recent and

Andre Turenne

Thank you.

Operator

Jim Fargo next with comes Wells Our Birchenough question from Securities.

Unidentified Analyst

This Hi, questions. for on taking Yanan thanks the for is Jim.

and program. wanted just the have Parkinson's follow-up I to a disease Huntington's disease a I So questions start on on program then with the few

there you able of the at And So for program, RESTORE-X? and would some activity enrollment provide for -- update you. any clinical biomarker data data for interim in enzyme before coverage and/or data, sort also RESTORE-X. Thank Parkinson's be putamen report any AADC analysis you an readout? the sometime on to before RESTORE-X possibility disease is And the would incremental also

Andre Turenne

the Yanan, Yes, program. PD thanks for questions, your on

So yet clearance. celebration HSR formally active we the for are our this, with Neurocrine to on start partner, waiting

the and get our a as start with earlier, of program site held pair new were meeting referring commenting the where we themselves the community of whole investigator the among got work further updates this enrollment on about we to to partner with year but the between reenergized of So the about share at and will we closely and status surgical where we it coordinate site. mentioning just study, investigators stand we with

lot there's of now and continued to really we'll very that's of fresh with the great this a of program. partner we resources the with the do able progress with enrollment be with our So expect momentum

have alignment provide that once So, we as we with Neurocrine. updates appropriate will

an considered serve look. one this optimal of two here, there studies interim we interim pivotal we in will a much this analysis, statistical to hit of determine the As but to the the too take is trials, development that of as as

updates to lead we work the will provide periodic that the again, to So with on all on will our XX progress look endpoint. Neurocrine readout able on But be to primary a have program. month fronts we to

Unidentified Analyst

the scaffold just ability as wondering, the of competitors in silence you candidate you. miRNA example the candidate for whether as able program, compare very miRNA on Huntington's inside Thank that's would AAV, differences well important. And with and to the Great, your helpful. to be disease might nucleus terms be

Andre Turenne

here. as chime HD to at we ask the Matt Dinah participate, start presenting I'll here, an actually she's conference speak, in and also Yanan. -- thanks, not Yes, I'll could

So, why and complete start response. you I the don't will Matt

Matt Osborne

then it's are constructs, gold particularly there large you where as are to a data products a different in result of trials, compare our think dosing that model Huntington's down on we and for the I cortical very across companies, Yes, the XX% knock think further putamen, three excited average aware, year. different animal and the and is different in that standard the saw the With difficult delivery, in move methods. profile different neurons, the we excited places ESGCT mammals, isn't at optimization said, very measured. different a later on we IND strong species, different XX% that in data, about later an in we're data strong past a being that this we -- on tested different where different filing to as saw time If shared fall, very track different being models, across that of held the forward points, this caudate, we XX% --

differentiation of very part In the we've cellularity seen on again terms want what in up your think got highly with with that modeling I but our comment [Ph], confident we question, the a we've strong profile constructs of second terms to this within point. to competitors' preclinical of robust wouldn't we're

Unidentified Analyst

Got helpful the for answers. Andre it. you Thank

Andre Turenne

Thanks Yanan.

Operator

comes Christianson Laura with question Our Cowen. from next

Laura Christianson

any you take, you're for curious been RESTORE-X. eligible waiting activation for will going enroll? long my is thus And have thanks activated just in the patients of queue have enrollment but how have think know how I centers Hi, many would about far? how I'm XX, And that to you that yet do be taking for activated question. sites not guidance targeting helpful. been if have the

Andre Turenne

Yes, thanks, Laura I'll Matt -- the to for question, Osborne ask

Matt Osborne

Laura. Hi, Sure.

of specific aware, going activation we're strong indicator in terms how progress the numbers very give but site again as depends of lagging made is the and you're clinicaltrials.gov of number on of a think, of bit neurology and I in terms So on surgical number you XX count year sites. it activation, we've to not a this

have sites. targeted nine total we of neurology XX a and surgery treating So sites

the treating a and last cases, refining same sites at We're the discussions as now those as of separate. we are neurology year of some in -- are of our the this look exploring at Neurocrine, additional a sized with Some having FDA also result and end working second for also support to support a study, our and toward delivery sites future also base study of whether commercialization. to larger the add that a pivotal not would thinking or strong

the to strong really we across can -- program next sure of the this that make be type of So enrollment to expect couple patients. the years drive of correct activating for we of sites number

consenting having second question around not they even IRB but of certainly study. they of and approval, detailed quite activated, part kind the cannot standards this have into well even their mind, they workshops The these IRB patients sites that of coming different those refining with know for that who with among investigator ahead in ideal ideas potential comply patients have yet would are your they to for be or super discussions patients be

momentum bring the the awareness to and that that to raise into activate, strong Neurocrine this we're sites on So working of trial, ability the collaboration things study. really how and sites of onto translates welcoming into look we that Michael the Foundation forward one is partnership with even more so awareness, the that our to patients will we feel increasing in the into increase broadly Fox J. adding right as

As past that expense measured signal go to not in from losing result appropriately. patients we right fast, the the the want of will we've the at of but course, described having

the And so comfortable we're very making there. we're progress with

Andre Turenne

add. just I'll

very in RESTORE-X we we've us progress since take feel January to and provided good made track terms to the to [Ph] enroll, we've guidance, guidance months to in we've the weeks we last XX month made months on expect be achieve XX the that In guidance a just so should progress fully that about that. of being the able that with

Laura Christianson

of hold And to one QX that's how what you do Perfect, had just just programs add outlined about you three think advance would independently. I'm to more, wanting of you to decide partner, one mentioned How that than rather you great. separate programs pathways that more kind make those on curious you into SODX then earlier. beyond would asset the

Matt Osborne

Yes.

moment, So assets have will of additional the of partners, lot wholly the as revamping noted a to portfolio. as on at added adding resources, and be owned done financial the the the focus capable portfolio we I

able So have from programs will we advance there, we have our added coming discovery to now out engine, to additional the potentially resources our be of look ALS, forward. and we that have able be -- outside with SODX to

table So, the important that we we own have continue have forward, that then but this to finance keep assets. owned wholly bring capable big indications to the gives to effort, both the and to move stake big us and our partners as stability have we'll picture again the in important ability mix

So they'll asset circumstances, an near-term, the in to but strategy. retained wholly continue given for assessment the the part we be of potentially look to to will add our

Laura Christianson

Great. questions. for taking Thanks my

Andre Turenne

you. Thank

Operator

Our last Jeff from Stanley. comes Morgan Hung, question

Jeff Hung

taking for the Thanks questions.

us can disease? need of think you you For you program, the slowing SODX remind to humans see down, magnitude clinically meaningful what in for of a knock

Matt Osborne

Hi, Matt Jeff, it's Osborne.

region, our cord, critical delivery when some animal cervical I spinal of we're both the translates we fall certainly strong to to the well region, respiratory an very XX% which released I that the would function. seeing average we ESGCT if get data again that extrapolate in think one the retaining are this directly you past in efficacy with into in we're XX% it's thoracic remind of into seen humans a above from difficult you answer comfortable rescue, models, hasn't there in that given it been yet, XX%,

And until very the humans, demonstrated sure, know clinic. one so can we're data about into but strong for that going actually again, feeling in no it's

Jeff Hung

how sales Okay. versus that guess are then the scenario Thanks in previously? would you potential co-promote need given the option about and in the thinking of ADC, for US, size force I you

Matt Osborne

I both companies kind with that to need where and it's at Neurocrine going in terms early be of sit we think very discuss down that are to point.

the to perhaps expect INGREZZA, successful because of most of before build advantages Neurocrine's of of available, they infrastructure, secondary probably a invest that it's infrastructure major but with our that in have Parkinson's, looks end these fully of centers would to doing for patients on in have targeted up Voyager. ahead Parkinson's movement this building what a a it But that of One fully force, of strong then in we of couple academic but have to for strong launch kind movement to so this time from and advanced even data just prepared areas. are ahead other is centers be are be away, that It's launch we have years expect that in a going which pretty the disorder collaboration a most products Voyager that all in they it had we like not community to could sales highly in the out that would optimize on disorder of -- the already a be own to well but had that again VY-AADC on most the larger the neurology. call large we

Jeff Hung

Okay, thank you.

Operator

gentlemen, and conclude I'd conference. of to portion for call remarks. to Ladies like the turn this does today's closing back Andre the Q&A

Andre Turenne

our does conclude call. that you, operator. Thank And

for on your our year. attending, throughout for everyone So progress thank questions, everyone updating look the forward you to

Operator

Ladies conclude presentation. this today's gentlemen, and does

You day.+ may now wonderful have and disconnect a

Voyager Therapeutics (VYGR) 26 Feb 192018 Q4 Earnings call transcript